Yitao Tian

Yitao Tian


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SHShaojie Hu
Shaojie Hu
CYChenxi Yan
Chenxi Yan
YTYitao Tian
Yitao Tian
WSWei Sun
Wei Sun
Neutrophils, which represent about 50–70% of circulating leukocytes in humans, have been viewed as short-lived effector cells of the innate immune system with a primary role in the clearance of pathogens and taking part in inflammatory processes. More recent evidence shows that neutrophils make up a significant portion of the inflammatory cell infiltration in many types of cancer, including non-small cell lung cancer (NSCLC). These tumor-associated neutrophils (TANs) can be divided into protumorigenic and antitumorigenic phenotypes. The biological features and functions of these TANs are under the influence of the tumor microenvironment. TANs also play a role in determining the responsiveness of NSCLC to immunotherapies targeting the programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) axis. This review aimed to summarize recent findings regarding the role of TANs in NSCLC progression and PD-1/PD-L1 targeted immunotherapy.

26 August 2025 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
CYChenxi Yan
Chenxi Yan
YCYanjie Chen
Yanjie Chen
YTYitao Tian
Yitao Tian
SHShaojie Hu
Shaojie Hu
HWHeng Wang
Heng Wang
WSWei Sun
Wei Sun
Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment efficacy and frequent resistance to conventional therapies. Recent advances have uncovered the critical influence of the human microbiota—complex communities of bacteria, viruses, fungi, and other microorganisms—on lung cancer pathogenesis and therapeutic responses. This review synthesizes current knowledge on the compositional and functional roles of microbiota across multiple body sites, including the gut, lung, tumor microenvironment, circulation, and oral cavity, highlighting their contributions to tumor initiation, progression, metastasis, and immune regulation. We emphasize the bidirectional communication between microbial metabolites and host immune pathways, particularly the gut–lung axis, which modulates systemic and local antitumor immunity. Importantly, microbiota composition has been linked to differential responses and toxicities in chemotherapy, radiotherapy, targeted therapy, and immune checkpoint blockade. Microbiota-targeted interventions, such as probiotics, fecal microbiota transplantation, and selective antibiotics, show promising potential to enhance treatment efficacy and mitigate adverse effects. However, challenges remain in clinical translation due to interindividual microbiome variability, mechanistic complexities, and limited longitudinal data. Future research integrating multi-omics, microbial functional profiling, and controlled clinical trials is essential to harness the microbiome as a precision medicine tool in lung cancer management. This review provides a comprehensive overview of the emerging role of microbiota in lung cancer development and therapy, offering new perspectives for innovative therapeutic strategies.